Lometrexol
Alternative Names: DDATHF; LY 264618; T 904064; T-64Latest Information Update: 24 Oct 2021
At a glance
- Originator Dana-Farber Cancer Institute
- Class 2 ring heterocyclic compounds; Amides; Glutamates; Pyrimidines
- Mechanism of Action DNA synthesis inhibitors; Phosphoribosylglycinamide formyltransferase inhibitors; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Sarcoma; Solid tumours
Most Recent Events
- 31 Jan 2003 Tularik has terminated its licensing agreement for T 64
- 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Australia (IV)
- 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Netherlands (IV)